HemoChat is an evidence-based AI medical search tool covering all major clinical domains, powered by 46,298 SNOMED-CT concepts, clinical guidelines, and live PubMed literature.

What medical domains does HemoChat cover?

HemoChat covers all major medical domains including cardiology, oncology, neurology, hematology, pulmonology, endocrinology, gastroenterology, psychiatry, nephrology, rheumatology, musculoskeletal, and more — with 46,298 SNOMED-CT concepts.

Is HemoChat a replacement for clinical judgment?

No. HemoChat is for clinical reference only and is not a substitute for professional medical judgment. Always consult qualified healthcare professionals for medical decisions.

What AI technology does HemoChat use?

HemoChat uses a hybrid GraphRAG + VectorRAG pipeline combining Neo4j knowledge graphs with FAISS vector search and an LLM for answer generation.

Glioma — Clinical Guidelines

Overview

Gliomas are primary brain tumors arising from glial cells, encompassing astrocytic, oligodendroglial, and mixed subtypes, classified by WHO grading systems based on histological features and molecular markers such as IDH mutation status. 4 23

Diagnosis

Clinical Presentation: Neurological deficits, seizures, cognitive changes.

Imaging: MRI is essential for tumor localization, extent, and grading. 1 9

Biopsy and Pathology: Neuropathological assessment with integrated morphological and molecular criteria (e.g., IDH mutation, 1p/19q codeletion). 2 24

Grading: WHO grading system (I-IV) based on cellularity, nuclear atypia, mitotic activity, and molecular markers. 4 23

Management

Surgical Resection: Maximal safe resection to reduce tumor burden and improve survival; awake craniotomy for eloquent areas. 1 11 17

Radiation Therapy: Standard for higher-grade gliomas (III-IV), considering dose and technique to minimize toxicity. 9

Chemotherapy: Temozolomide for newly diagnosed glioblastoma (WHO IV); specific regimens for lower-grade gliomas based on molecular profile. 12

Targeted Therapy: Emerging treatments like GD2-targeting CAR T cells show promise in specific molecular subtypes (e.g., H3K27M mutations). 10

Palliative Care: Early integration to manage symptoms and improve quality of life throughout the disease course. 22

Special Populations

Pediatrics: Focus on low-grade gliomas with IDH mutations; tailored management considering developmental impact. 4

Elderly: Consider comorbidities and functional status; less aggressive approaches may be appropriate. 12

Comorbidities: Increased vigilance for venous thromboembolism, especially in postoperative patients; manage anticoagulation risks carefully. 6 25

Key Recommendations

Maximize Safe Resection: Employ awake craniotomy techniques to achieve maximal resection in gliomas near eloquent cortex, improving functional outcomes. (Evidence: Strong 1 11)

Integrate Molecular Diagnostics: Use IDH mutation status and other molecular markers for accurate grading and guide treatment decisions in diffuse gliomas. (Evidence: Strong 4 23)

Consider Early Palliative Care: Integrate palliative care early in the disease trajectory to address symptom clusters and enhance quality of life. (Evidence: Moderate 22)

Monitor VTE Risk: Vigilantly manage anticoagulation in glioma patients, especially postoperatively, due to increased risk of intracranial hemorrhage. (Evidence: Moderate 6 25)

References

1 Goldbrunner R, Foroglou N, Signorelli F, Schucht P, Jakola AS, Minniti G et al.. EANS-EANO guidelines on the extent of resection in gliomas. Neuro-oncology 2026. link 2 Mandelberg N, Hodges TR, Wang TJC, McGranahan T, Olson JJ, Orringer DA. Congress of Neurological Surgeons systematic review and evidence based guideline on neuropathology for WHO grade II diffuse glioma: update. Journal of neuro-oncology 2025. link 3 Yang W, Jian M, Wang X, Zhou Y, Liang Y, Chen Y et al.. Dynamic Cortical Connectivity During Propofol Sedation in Glioma Patients. Journal of neurosurgical anesthesiology 2025. link 4 Vaz-Salgado MÁ, García BC, Pérez IF, Munárriz BJ, Domarco PS, González AH et al.. SEOM-GEINO clinical guidelines for grade 2 gliomas (2023). Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico 2024. link 5 . Gliomas Hijack Adaptive Plasticity to Strengthen Neuron-Tumor Synapses. Cancer discovery 2024. link 6 Huo H, Shen S, Yang Y, Zhang H, Wu S, Bi T et al.. The risk of intracranial hemorrhage in glioma patients receiving anticoagulant treatment for venous thromboembolism: a bayesian network meta-analysis. Journal of thrombosis and thrombolysis 2023. link 7 Baek AE. Neuronal-glioma cross-talk. Science signaling 2023. link 8 . Glioma Infiltration and Progression Are Driven by Remote Neuronal Activation. Cancer discovery 2023. link 9 Antoni D, Feuvret L, Biau J, Robert C, Mazeron JJ, Noël G. Radiation guidelines for gliomas. Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique 2022. link 10 . GD2-Targeting CAR T Cells Show Promise in H3K27M-Mutated Gliomas. Cancer discovery 2022. link 11 Murcia D, D'Souza S, Abozeid M, Thompson JA, Djoyum TD, Ormond DR. Investigation of Asleep versus Awake Motor Mapping in Resective Brain Surgery. World neurosurgery 2022. link 12 Jiang T, Nam DH, Ram Z, Poon WS, Wang J, Boldbaatar D et al.. Clinical practice guidelines for the management of adult diffuse gliomas. Cancer letters 2021. link 13 . Epigenetic Heterogeneity Controls Glioma Cell State and Stress Response. Cancer discovery 2021. link 14 Rui W, Pang H, Xie Q, Wang Y, Duan S, Ren Y et al.. Association Between Histopathology and Magnetic Resonance Imaging Texture in Grading Gliomas Based on Intraoperative Magnetic Resonance Navigated Stereotactic Biopsy. Journal of computer assisted tomography 2021. link 15 Kluckova K, Kozak J, Szaboova K, Suchankova M, Svajdler M, Blazickova S et al.. Low serum vitamin D levels are associated with a low percentage of TREM-2+ monocytes in low-grade gliomas and poorer overall survival in patients with high-grade gliomas. Bratislavske lekarske listy 2021. link 16 . Hypermutated Gliomas Respond Poorly to Immunotherapy. Cancer discovery 2020. link 17 Coomans MB, Dirven L, Aaronson NK, Baumert BG, Van Den Bent M, Bottomley A et al.. Symptom clusters in newly diagnosed glioma patients: which symptom clusters are independently associated with functioning and global health status?. Neuro-oncology 2019. link 18 Prokhorova IV, Pyaskovskaya ON, Kolesnik DL, Solyanik GI. Influence of metformin, sodium dichloroacetate and their combination on the hematological and biochemical blood parameters of rats with gliomas C6. Experimental oncology 2018. link 19 Southwell DG, Birk HS, Han SJ, Li J, Sall JW, Berger MS. Resection of gliomas deemed inoperable by neurosurgeons based on preoperative imaging studies. Journal of neurosurgery 2018. link 20 Suero Molina E, Schipmann S, Mueller I, Wölfer J, Ewelt C, Maas M et al.. Conscious sedation with dexmedetomidine compared with asleep-awake-asleep craniotomies in glioma surgery: an analysis of 180 patients. Journal of neurosurgery 2018. link 21 Nielsen LAG, Bangsø JA, Lindahl KH, Dahlrot RH, Hjelmborg JVB, Hansen S et al.. Evaluation of the proliferation marker Ki-67 in gliomas: Interobserver variability and digital quantification. Diagnostic pathology 2018. link 22 Pace A, Dirven L, Koekkoek JAF, Golla H, Fleming J, Rudà R et al.. European Association for Neuro-Oncology (EANO) guidelines for palliative care in adults with glioma. The Lancet. Oncology 2017. link30345-5) 23 Ferris SP, Hofmann JW, Solomon DA, Perry A. Characterization of gliomas: from morphology to molecules. Virchows Archiv : an international journal of pathology 2017. link 24 Woehrer A, Kristensen BW, Vital A, Hainfellner JA. Patterns of diagnostic marker assessment in adult diffuse glioma: a survey of the European Confederation of Neuropathological Societies (Euro-CNS). Clinical neuropathology 2017. link 25 Morgan ER, Mason WP, Maurice C. A critical balance: managing coagulation in patients with glioma. Expert review of neurotherapeutics 2016. link 26 Southwell DG, Hervey-Jumper SL, Perry DW, Berger MS. Intraoperative mapping during repeat awake craniotomy reveals the functional plasticity of adult cortex. Journal of neurosurgery 2016. link 27 Trimble G, McStravick C, Farling P, Megaw K, McKinstry S, Smyth G et al.. Awake craniotomy for glioma resection: Technical aspects and initial results in a single institution. British journal of neurosurgery 2015. link 28 Kaneria A. Opioid-induced hyperalgesia: when pain killers make pain worse. BMJ case reports 2014. link 29 Okada H, Scheurer ME, Sarkar SN, Bondy ML. Integration of epidemiology, immunobiology, and translational research for brain tumors. Annals of the New York Academy of Sciences 2013. link 30 Lima J. Venous thromboembolism and gliomas: the need for increased vigilance. Clinical journal of oncology nursing 2011. link 31 Peruzzi P, Bergese SD, Viloria A, Puente EG, Abdel-Rasoul M, Chiocca EA. A retrospective cohort-matched comparison of conscious sedation versus general anesthesia for supratentorial glioma resection. Clinical article. Journal of neurosurgery 2011. link 32 Higgins SC, Steingrimsdottir H, Pilkington GJ. Human, mouse or rat? Species authentication of glioma-derived cell cultures. Journal of neuroscience methods 2010. link 33 Price SJ, Fryer TD, Cleij MC, Dean AF, Joseph J, Salvador R et al.. Imaging regional variation of cellular proliferation in gliomas using 3'-deoxy-3'-[18F]fluorothymidine positron-emission tomography: an image-guided biopsy study. Clinical radiology 2009. link 34 Pinsker MO, Nabavi A, Mehdorn HM. Neuronavigation and resection of lesions located in eloquent brain areas under local anesthesia and neuropsychological-neurophysiological monitoring. Minimally invasive neurosurgery : MIN 2007. link 35 Hata N, Muragaki Y, Inomata T, Maruyama T, Iseki H, Hori T et al.. Intraoperative tumor segmentation and volume measurement in MRI-guided glioma surgery for tumor resection rate control. Academic radiology 2005. link 36 Marquez A, Wu R, Zhao J, Tao J, Shi Z. Evaluation of epidermal growth factor receptor (EGFR) by chromogenic in situ hybridization (CISH) and immunohistochemistry (IHC) in archival gliomas using bright-field microscopy. Diagnostic molecular pathology : the American journal of surgical pathology, part B 2004. link 37 Jääskeläinen J, Randell T. Awake craniotomy in glioma surgery. Acta neurochirurgica. Supplement 2003. link 38 Viapiano MS, Matthews RT, Hockfield S. A novel membrane-associated glycovariant of BEHAB/brevican is up-regulated during rat brain development and in a rat model of invasive glioma. The Journal of biological chemistry 2003. link 39 Whittle IR. Surgery for gliomas. Current opinion in neurology 2002. link 40 Meyer FB, Bates LM, Goerss SJ, Friedman JA, Windschitl WL, Duffy JR et al.. Awake craniotomy for aggressive resection of primary gliomas located in eloquent brain. Mayo Clinic proceedings 2001. link 41 Collingridge DR, Piepmeier JM, Rockwell S, Knisely JP. Polarographic measurements of oxygen tension in human glioma and surrounding peritumoural brain tissue. Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology 1999. link00121-8) 42 Bouzier AK, Voisin P, Goodwin R, Canioni P, Merle M. Glucose and lactate metabolism in C6 glioma cells: evidence for the preferential utilization of lactate for cell oxidative metabolism. Developmental neuroscience 1998. link 43 Uzal D, Ozyar E, Tükül A, Genç M, Söylemezoğlu F, Atahan IL et al.. Familial glioma in two siblings. Radiation medicine 1996. link 44 van Meyel DJ, Ramsay DA, Casson AG, Keeney M, Chambers AF, Cairncross JG. p53 mutation, expression, and DNA ploidy in evolving gliomas: evidence for two pathways of progression. Journal of the National Cancer Institute 1994. link 45 Hammacher A, Nistér M, Westermark B, Heldin CH. A human glioma cell line secretes three structurally and functionally different dimeric forms of platelet-derived growth factor. European journal of biochemistry 1988. link 46 Saya H, Masuko T, Kokunai T, Yagita H, Ijichi A, Taomoto K et al.. Detection of human glioma-associated antigen by rat monoclonal antibody raised against syngeneic rat glioma cells. Journal of neurosurgery 1986. link 47 Vandevelde M, Fankhauser R, Luginbühl H. Immunocytochemical studies in canine neuroectodermal brain tumors. Acta neuropathologica 1985. link 48 Kumanishi T, Watabe K, Washiyama K. An immunohistochemical study of aldolase C in normal and neoplastic nervous tissues. Acta neuropathologica 1985. link 49 Bourdon MA, Matthews TJ, Pizzo SV, Bigner DD. Immunochemical and biochemical characterization of a glioma-associated extracellular matrix glycoprotein. Journal of cellular biochemistry 1985. link 50 Weisberg LA, Dunn D. Thalamic gliomas: clinical and computed tomographic correlations. Computerized radiology : official journal of the Computerized Tomography Society 1983. link90147-6) 51 Wilson KS, Brigden ML, Alexander S, Worth A. Fatal pneumothorax in "BCNU lung". Medical and pediatric oncology 1982. link 52 Brunsting HA. Nasal glioma. Cutis 1981. link 53 de Tribolet N, Deruaz JP, Zander E. Familial gliomas. Neurochirurgia 1979. link 54 Lee SH, Osborn MA, Buchheit WA. Glioma of the jugular foramen. Case report. Journal of neurosurgery 1976. link

Glioma